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Abstract: The efficacy of antibiotic monotherapy and combination therapy in the treatment of 
implant-associated infection by Staphylococcus aureus was evaluated in an animal study. The 
femoral medullary cavity of 66 male Wistar rats was contaminated with S. aureus (ATCC 29213) 
and a metal device was implanted, of which 61 could be evaluated. Six treatment groups were 
studied: flucloxacillin, flucloxacillin in combination with rifampin, moxifloxacin, moxifloxacin 
in combination with rifampin, rifampin, and a control group with aqua. The treatment was 
applied for 14 days. After euthanasia, the bacterial counts in the periprosthetic bone, the soft 
tissue, and the implant-associated biofilm were measured. Both antibiotic combination treat-
ments (moxifloxacin plus rifampin and flucloxacillin plus rifampin) achieved a highly significant 
decrease in microbial counts in the bone and soft tissue and in the biofilm. Mono-antibiotic 
treatments with either moxifloxacin or flucloxacillin were unable to achieve a significant 
decrease in microbial counts in bone and soft tissue or the biofilm, whilst rifampin was able to 
reduce the counts significantly only in the biofilm. Antibiotic resistance was measured in 1/3 
of the cases in the rifampin group, whereas no resistance was measured in all other groups. 
The results show that combinations of both moxifloxacin and flucloxacillin plus rifampin are 
adequate for the treatment of periprosthetic infections due to infections with S. aureus, whereas 
monotherapies are not effective or not applicable due to the rapid development of antibiotic 
resistance. Therefore, moxifloxacin is an effective alternative in combination with rifampin for 
the treatment of implant-associated infections.
Keywords: moxifloxacin, rifampin, flucloxacillin, implant-associated infection, prosthetic 
infection, Staphylococcus aureus
Introduction
Periprosthetic joint infections cause considerable mortality and morbidity in patients 
with joint arthroplasty. Due to the increasing number of interventions in primary joint 
replacement, the numbers of revision surgery following infection have been rising 
steadily. The choice of appropriate antibiotic therapy is still a challenge in the treatment 
of periprosthetic joint infection. In the treatment of staphylococcal infections, rifampin 
plays an important role.1 Due to the rapid development of resistance to rifampin in 
monotherapy, either a staphylococcal penicillin (ie, flucloxacillin) or a fluoroquinolone 
(ie, ciprofloxacin or levofloxacin) should be added for sufficient therapy. The antibiotic 
standard treatment of prosthesis infection by methicillin-sensitive staphylococcus 
currently consists of a combination of initial intravenous therapy with flucloxacillin 
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and rifampin followed by a combination of an older quinolone 
(ie, ciprofloxacin or levofloxacin) with rifampin. Since many 
antibiotics that are able to penetrate into bone tissue, such 
as oxacillin, should be applied ideally parenterally, the 
treatment is often associated with a long hospitalization. 
Newer quinolones like moxifloxacin are possible combina-
tion partners, which were supposed to be examined more 
closely in this study due to their improved spectrum of 
activity against gram positive, gram negative, and anaerobic 
pathogens as well as their good oral bioavailability, activity, 
and safety.2 The superiority of moxifloxacin compared 
with vancomycin was demonstrated in the treatment of 
prosthetic infections.3 In addition, the oral bioavailability is 
almost as high as on parenteral administration.4 In numerous 
in vitro and in vivo studies, moxifloxacin was much more 
effective against staphylococci than older fluoroquinolones 
such as ciprofloxacin.5–10 Other studies demonstrated that 
moxifloxacin is capable of penetrating rapidly into infected 
soft and bone tissue.11–13
Our working group could successfully achieve bacterial 
contamination with intramedullary foreign body implantation 
in a minimally invasive technique and subsequent 14-day anti-
biotic treatment in rats in already completed animal studies; 
the local rate of infection in this animal model was 100%.3,14
To assess the antibiotic efficacy in implant-associated 
infections of the clinically frequently used moxifloxacin 
(group M), flucloxacillin (group F), rifampin (group R), and 
the combination of moxifloxacin plus rifampin (group MR) 
and flucloxacillin plus rifampin (group FR), compared to a 
placebo group (group A), the present controlled animal study 
was performed.
Materials and methods
animals
The controlled animal study was performed after approval by 
the local and state animal protection committee (Regierung 
der Oberpfalz, Bavaria, Germany; approval application no 
54-2531.1-21/06). All animal experiments were carried out 
in accordance with the European (EU) Directive 2010/63/EU. 
The study used 66 male Wistar rats (Charles River, Sulzfeld, 
Germany), of which 61 were included in the analysis. At the 
beginning of the study, the animals were aged 12–14 weeks. 
Bacterial strain
For experimental contamination, a bacterial strain of 
Staphylococcus aureus (ATCC 29213; American Type 
Culture Collection, Manassas, VA, USA) was used. This 
particular strain is known to be penicillin-resistant and 
oxacillin-sensitive. The bacterial suspensions prepared 
from logarithmically growing cultures contained 108 colony-
forming units (CFU)/mL.
experimental technique
On day 0, all experimental animals were anesthetized and 
a sterilized hollow steel needle 1.5 cm ×1.0 mm from an 
intravenous catheter 18G was implanted retrogradely into 
the left femur after parapatellar incision. Next, the bacterial 
suspension was introduced into the medullary cavity (100 µL 
with 108 CFU/mL of S. aureus). Afterward, the distal femur 
was sealed by bone wax, the joint was irrigated, and the 
wound was closed.
Antibiotic treatment
Following implantation, on day 7, antibiotic treatment was 
started. The rats were randomized into six groups (rifampin, 
flucloxacillin, moxifloxacin, rifampin plus moxifloxacin, 
flucloxacillin plus rifampin, aqua [control group], referred 
to as groups M, F, R, MR, FR, and A).
Antibiotics used were flucloxacillin 1 g (Delta Select 
GmbH, Dreieich/Pfullingen, Germany), moxifloxacin hydro-
chloride (Bayer HealthCare AG, Wuppertal, Germany), 
and rifampin 600 mg sodium (Fatol Arzneimittel GmbH, 
Schiffweiler, Germany). Intraperitoneal applied doses were 
200 mg/kg body weight flucloxacillin three times/day, 
20 mg/kg body weight rifampin once daily, 10 mg/kg body 
weight moxifloxacin two times/day, and 0.4 mL aqua two 
or three times/day without any change of doses in the above 
listed groups of combined therapy. The treatment was given 
until day 21.
Termination criteria included fracture of the operated 
femur with signs of instability, wound healing disorders, 
systemic septic reaction. In order to document the effects of 
surgery and antibiotic treatment, body weight was checked 
at day 0, 8, 15, and 23. 
Microbiological analysis
On day 23 of the experiment, the animals were anesthetized 
and euthanized 48 hours after the last administration of antibi-
otics, and the contaminated legs were explanted under sterile 
conditions. The periarticular soft tissues, femur, and the 
implant with biofilm were separated and microbiologically 
analyzed directly. As already described in previous studies 
concerning microbial infection and antibiotic treatment of 
implants realized in our department,3 both bone and soft tissue 
were frozen after extraction with liquid nitrogen, then homog-
enized in a dismembranator (Braun, Melsungen, Germany), 
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and resuspended mechanically with 4 mL of 0.9% saline 
at 250 rpm (Vortex Genie 2; Bender & Hobein, Zürich, 
Switzerland).
To remove the biofilm, samples were placed in an ultra-
sonic bath and then cleaned mechanically in the same way 
as before with the bone and soft tissue. Afterward, 50 µL 
suspensions of biofilm, bone, and soft tissue, respectively, 
were plated onto tryptic soy agar plates in dilution series 
using a semiautomatic spiral platter (Whitley Automatic 
Spiral platter; Don Whitley Scientific, Shipley, UK). After 
48 hours of incubation at 36°C, CFU/mL were counted 
blinded to treatment. The detection limit of the culture 
systems is 20 CFU/mL and absence of S. aureus colonies 
was defined as sterile. 
In order to evaluate systemically induced infection or 
contamination, the contralateral (right) hind leg was also 
examined in all experimental animals.
Decision criteria
In group FR, one animal had to be eliminated from the study 
because of postoperatively increasing systemic septic reactions, 
meeting termination criteria as defined above. Four animals 
died perioperatively or during the course of the experiment 
(one each in groups A, M, F, and FR). Thus, a total of 61 of 
the 66 animals were included in the final evaluation.
Three animals showed extramedullary location of the 
implant. However, as they still showed an infection of both 
implant and adjacent femur, they were nonetheless included 
in the statistical analysis.
statistical analysis
The study design of the main experiment is based on a 
placebo-controlled parallel trial with randomized experi-
mental groups. The size of the study groups, number of 
animals within each group, was determined on the basis of 
previous studies.3 Analysis of a group size of n=9 showed a 
statistical power of 0.8 and a type I error alpha =0.05. Groups 
comprised 11 animals because possible complications during 
the experiment had to be taken into account. 
For statistical analysis, a P-value ,0.05 was considered 
to be statistically significant. The Mann–Whitney U-test for 
non normally distributed values was used (SigmaStat 3.1; 
SYSTAT Software Inc., Point Richmond, Richmond, CA, 
USA). For graphical representation, box plots were used.
Results
The body weight at the end of experiments did not signifi-
cantly differ compared to the beginning of experiments.
In all infected knee joints, there were clear macroscopic 
signs of infection such as empyema, purulent arthritis 
with periarticular bone destruction and osteomyelitis with 
periprosthetic pus after explantation. In group A (control 
group), an aggravation especially of the bone defects could 
be seen. Samples from the right hind leg were sterile in all 
animals; the infection thus remained localized.
In the probes of the periarticular tissue, median bacterial 
counts of S. aureus were as follows: group A log 4.47 CFU/g 
(standard deviation [SD] log 5.73 CFU/g), group F log 
4.42 CFU/g (SD log 6.02 CFU/g), group FR log ~0 CFU/g 
(SD log 3.51 CFU/g), group M log 2.83 CFU/g (SD log 
4.75 CFU/g), group MR log ~0 CFU/g (SD log 3.12 CFU/g), 
group R log 2.81 CFU/g (SD log 4.59 CFU/g). The probes 
of the periarticular tissue showed negative results concern-
ing the growth of bacteria in seven animals of group MR 
and eight animals of group FR. The highest bacterial counts 
were measured in group A, F, and R. As already mentioned, 
bacteria could be cultured only once in group FR; therefore, 
a significant reduction of bacterial count could be seen 
compared to group F (P=0.002) and group A (P=0.003), but 
no significant difference compared to group R (P=0.190). 
Group MR also showed a significant reduction of bacterial 
count in comparison to group F (P=0.002) and group A 
(P=0.006), but no significant reduction compared to 
group R (P=0.448). Furthermore, comparison between 
groups F and M showed that the difference of bacterial 
count was significant (P=0.037), favoring monotherapy 
using moxifloxacin. There was no significant difference 
upon comparing the combination therapy groups FR and 
MR (P=0.386) (Figure 1).
In the probes of the femur, median bacterial counts of 
S. aureus were as follows: group A log 5.14 CFU/g (SD log 
5.54 CFU/g), group F log 3.79 CFU/g (SD log 5.31 CFU/g), 
group FR log ~0 CFU/g (SD log 1.92 CFU/g), group M log 
3.09 CFU/g (SD log 4.73 CFU/g), group MR log ~0 CFU/g 
(SD log 1.70 CFU/g), group R log 1.27 CFU/g (SD log 
5.31 CFU/g).
In the femur, in both groups MR and FR only two animals 
had positive cultures of S. aureus; all other groups had 
positives cultures in all animals. Considering this, bacterial 
counts in the femur of groups FR and MR were significantly 
lower than in group A, F, and M (P=0.001 each). Still, there 
was no significant difference compared to group R (FR/R 
P=0.357, MR/R P=0.263). The comparison between group F 
and group M showed no significant difference of bacterial 
count (P=0.168), similar to the comparison between FR and 
MR (P=0.836) (Figure 2).
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In samples obtained from biofilms, median bacterial 
counts of S. aureus were as follows: group A log 3.91 CFU/g 
(SD log 5.60 CFU/g), group F log ~0 CFU/g (SD log 
2.70 CFU/g), group FR log ~0 CFU/g (SD log 1.52 CFU/g), 
group M log 2.15 CFU/g (SD log 2.82 CFU/g), group MR 
log ~0 CFU/g (SD log 0.00 CFU/g), group R log 1.3 CFU/g 
(SD log 3.05 CFU/g).
The biofilms removed from the implants were sterile 
in group MR, sterile with one exception in group FR, and 
sterile in six of 10 cases in group F. In the statistical analysis, 
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Figure 1 Bacterial counts in the soft tissue of the knee joint after 14 days of therapy with aqua (control group A), flucloxacillin (group F), flucloxacillin in combination with 
rifampin (group FR), moxifloxacin (group M), moxifloxacin in combination with rifampin (group MR), and rifampin (group R). 
Notes: The boundaries of the box indicate the 25th and 75th percentiles; whiskers above and below the box indicate the 95th and fifth percentiles. Significant bacterial count 
reduction is marked with braces below the graph. P,0.05.
Abbreviation: CFU, colony-forming units.
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Figure 2 Bacterial counts in the femoral bone after 14 days of therapy with aqua (control group A), flucloxacillin (group F), flucloxacillin in combination with rifampin 
(group FR), moxifloxacin (group M), moxifloxacin in combination with rifampin (group MR), and rifampin (group R). 
Notes: The boundaries of the box indicate the 25th and 75th percentiles; whiskers above and below the box indicate the 95th and fifth percentiles. Significant bacterial count 
reduction is marked with braces below the graph. P,0.05. 
Abbreviation: CFU, colony-forming units.
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group FR was significantly better in bacterial counts than 
group M (P=0.024), group MR was better than group M 
(P=0.009), and both groups FR and MR were superior to 
group R (P=0.021; P=0.005) with no significant difference 
between groups F and M (P=0.405), and groups FR and MR 
(P=0.707) (Figure 3).
In 1/3 of group R cases, antibiotic resistance was mea-
sured, whereas no antibiotic resistance was measured in 
groups M, F, FR, and MR.
Discussion
Periprosthetic joint infection is a serious complication after arti-
ficial joint replacement, which is accompanied by a significant 
psychological and physical burden for the patient and repre-
sents a significant financial burden for health care.15 Due to 
age structure and the world’s growing number of prosthetic 
implants and prosthesis replacement operations, periprosthetic 
joint infection will continue to play an even greater role. By 
optimization of operative techniques, implants, and hygiene, 
the incidence of periprosthetic infections in primary arthro-
plasty has been reduced to 1%–2%,15–17 but especially in revi-
sion operations the incidence is still much higher.18
In addition to surgical revision and, if necessary, one- or 
two-stage prosthesis exchange, antibiotic treatment plays 
an important role for successful treatment in periprosthetic 
joint infection. To improve antibiotic treatment, considering 
increasing resistance rates as well, this efficacy investigating 
animal study of our already well established animal model 
was applied.3
One of the most important antibiotics in the treatment 
of periprosthetic joint infection is rifampin. Rifampin is a 
cornerstone in the treatment of prosthetic infection as it is 
active against staphylococci including methicillin-resistant 
S. aureus, can be given orally, has very good bioavailability, 
and is well tolerated.19 Due to the rapid development of 
resistance, it should not be used as monotherapy1 which has 
already been proven by O’Reilly in 199220 who showed that 
combination therapy is superior to monotherapy.
In clinical practice, rifampin is often initially combined 
with flucloxacillin, proven to have good activity and bioavail-
ability against staphylococci. The initial treatment is given 
intravenously and then switched to oral antibiotic therapy 
after 2 weeks due to the simpler, outpatient treatment.
The most common combination partner nowadays is a 
quinolone (ie, ciprofloxacin) because it has a better spectrum 
of activity and good oral bioavailability, is well tolerated, 
and achieves high intracellular concentrations. It also demon-
strates intracellular activity against staphylococci.19,21 Clinical 
trials with various quinolones confirmed the effectiveness of 
the combination therapy.1,6,22 New fluoroquinolones like 
levofloxacin or moxifloxacin differ from the quinolones of 
the first generation by a broader spectrum of activity includ-
ing Gram positive bacteria, excellent pharmacokinetics 
with good tissue penetration, good oral bioavailability, and 
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Figure 3 Bacterial counts in the implant-adherent biofilm after 14 days of therapy with aqua (control group A), flucloxacillin (group F), flucloxacillin in combination with 
rifampin (group FR), moxifloxacin (group M), moxifloxacin in combination with rifampin (group MR), and rifampin (group R). 
Notes: The boundaries of the box indicate the 25th and 75th percentiles; whiskers above and below the box indicate the 95th and fifth percentiles. Significant bacterial count 
reduction is marked with braces below the graph. P,0.05. 
Abbreviation: CFU, colony-forming units.
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lesser side effects.23 The development of resistance during 
therapy with moxifloxacin appears to be smaller than with 
older quinolones.24–26
The current experimental animal study was supposed 
to evaluate the efficacy of newer quinolones such as moxi-
floxacin in the treatment of periprosthetic infection in order 
to determine its function as a valid alternative to treatments 
already in practice.
By choosing an intraosseous position of the foreign body, 
we were able to simulate a situation much closer to reality than 
previously published models such as the subcutaneous animal 
cage models Lucet,27 Chuard,28 and Zimmerli29 described 
or the intra-abdominal foreign body-associated abscess of 
Espersen30,31 or Gallimore,32 who could only evaluate the 
mechanisms and physiology of a foreign body infection.
By implanting a foreign body into the femur and intro-
ducing a solution carrying a specific, penicillin-resistant, and 
oxacillin-sensitive specimen, the local infection rate obtained 
was 100% used in our predescribed model.3 As expected, the 
most serious infection appeared in the animals of the control 
group who did not receive antibiotic therapy.
It could be proven that moxifloxacin in combination with 
rifampin was as effective as the combination of flucloxacil-
lin and rifampin. Only in the groups of combined antibiotic 
treatment the majority of samples were sterile. Neither 
monotherapy with moxifloxacin nor flucloxacillin was able 
to achieve a relevant reduction of germs. Nonetheless, in 
the biofilm of the implant, in contrast to soft tissue and bone 
samples, the monotherapies were superior to the control 
group which indicates the effectiveness of both antibiotics 
against bacteria in the biofilm. Rifampin monotherapy 
showed significant bacteria reduction in the biofilm and in 
the bone tissue compared to the control group. Still, it should 
be kept in mind that a rapid development of resistance has 
been seen under monotherapy with rifampin in 1/3 of the 
cases, as described in the literature.
Both moxifloxacin and flucloxacillin are especially 
effective against the most common bacterial strains in 
periprosthetic infection. In contrast to moxifloxacin, flu-
cloxacillin is a penicillin only active against staphylococci 
and therefore has a very narrow spectrum of action. Due to 
the short half-life and the necessary parenteral administra-
tion to ensure high bioavailability it is inferior to quinolones. 
In summary, the most important advantage of quinolo-
nes against oxacillin in clinical practice is the good oral 
bioavailability with comparable tissue concentrations after 
both intravenous and oral administration. Therefore, it is 
possible to begin with a short intravenous therapy and convert 
into an oral therapy without changing the antibiotic which 
gives the possibility to both stay with an effective treatment, 
reduce development of resistance by unnecessary changes of 
antibiotics, and possibly reduce hospital length of stay, reduce 
costs, and enable an outpatient setting earlier. Furthermore, 
moxifloxacin can be given as a single dose of 400 mg/day 
due to long half-life and favorable pharmacokinetics.11,12,33,34 
Reduction of the amount of pills to be taken daily is known 
to lead to a higher acceptance of the treatment and therefore 
compliance by patients.
Limitations
The limitation of this study is certainly the setting of an ideal-
ized animal experimental study with a small sample size of 
11 animals per test group. Furthermore, the blood levels and 
therapeutic power of an agent administered intraperitoneally 
in animals might be different compared to intravenous or oral 
administration in human beings. Further clinical studies to 
assess these aspects are needed. Systemic antibiotic therapy 
is only one part in the effective treatment of periprosthetic 
joint infection, still probably the part that can and will be 
influenced most in the future. Effective and targeted use of 
antibiotics will improve the success of combined surgical 
and medical therapy.
Conclusion
In the present experimental animal study, both the combina-
tions of flucloxacillin/rifampin and moxifloxacin/rifampin 
were found to be effective in the treatment of S. aureus causing 
periprosthetic joint infection. At equivalent effectiveness, due 
to many other advantages such as improved pharmacokinetics, 
the possibility of a single oral dose daily, extended activity 
spectrum compared to flucloxacillin and older quinolones, 
and currently better resistance profile, moxifloxacin combined 
with rifampin is a promising alternative in the treatment of 
periprosthetic joint infections, for example, in an outpatient 
setting. The central role of rifampin as one of the most 
potent antibiotics in combination therapy of periprosthetic 
joint infection is clearly confirmed by the present study.
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